

What you need to know

The Nu.Q® Vet Cancer Screening Test is:

- Non-invasive – just a simple blood draw (dog should be fasted minimum of four hours)
- Affordable, no need for sedation
- Reliable – identifies 82% of hemangiosarcoma and 77% of lymphoma

Early data shows Nu.Q® Vet may also be a useful monitoring test for dogs with cancer.

To find out more ask your Veterinarian, email AskNu.QVet@volition.com or call the AskNu.Q® Vet Hotline on 979-709-2348



Introducing the Nu.Q® Vet Cancer Screening Test



Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. VVDD01.2 – Printed December 2021.

Volition 
Veterinary

nu·q
vet

Cancer is the most common cause of death in dogs over the age of 2 years in the US.

Up to 50% of all dogs over the age of 10 will develop cancer in their lifetimes.

With approximately 77 million pet dogs in the United States, there are an estimated 6 million pet dogs diagnosed with cancer each year.

Earlier detection of cancer can not only help save lives, it can also improve the quality of life of the dog and more quality time with its owner.

Yet, as of today, unlike the human healthcare world where screening for certain cancers is commonplace (mammogram for breast cancer, colonoscopy for colorectal cancer, HPV for cervical cancer, to name but a few) there are few cancer screening tests on the veterinary market.


Currently, dogs are typically diagnosed when they are unwell or there is a suspicion of cancer. Even then dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming and/or painful for the animal.

We hope to change this with the introduction of the Nu.Q® Vet Cancer Screening Test – a simple, low-cost, easy to use screening blood test to be used with the annual wellness check for older dogs (7 years and older), and may also be a complementary test for younger dogs (4 years and older) with an increased risk for developing cancer in their lifetimes such as, Golden Retriever, Labrador Retriever, French Bulldog, Boxer, Beagle, German Shepherd, Bernese Mountain Dog, Siberian Husky, Rottweiler, Great Dane, Irish Wolfhound, Scottish Deerhound, Mastiff, Flat Coated Retriever.

The Nu.Q® Vet Cancer Screening Test has been shown to detect lymphoma and hemangiosarcoma, common cancers which make up approximately one third of canine cancers.

We believe using the Nu.Q® Vet Cancer Screening Test can help streamline the diagnostic process and shorten the path to diagnosis thereby allowing treatment (be that therapy or surgery) to be initiated earlier, thus providing better quality of life to the pet and more quality time with its owners, as well as providing valuable additional information to inform the clinical decision-making process.

This revolutionary product has been developed in collaboration with Texas A&M University and the results of key studies have been presented at the world's leading veterinary oncology conferences and published in peer reviewed journals.



"The Nu.Q® Vet Cancer Screening Test has been shown to detect lymphoma and hemangiosarcoma, common cancers which make up approximately one third of canine cancers."